Thermo Fisher Scientific (TMO) – Analysts’ Weekly Ratings Updates

Posted by Micah Haroldson on May 2nd, 2024

Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

4/30/2024 – Thermo Fisher Scientific had its price target raised by analysts at HSBC Holdings plc from $660.00 to $670.00. They now have a “buy” rating on the stock.
4/25/2024 – Thermo Fisher Scientific had its price target raised by analysts at JPMorgan Chase & Co. from $600.00 to $650.00. They now have an “overweight” rating on the stock.
4/25/2024 – Thermo Fisher Scientific had its price target lowered by analysts at Robert W. Baird from $621.00 to $620.00. They now have an “outperform” rating on the stock.
4/25/2024 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $590.00 to $615.00. They now have an “equal weight” rating on the stock.
4/25/2024 – Thermo Fisher Scientific had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $600.00 to $610.00. They now have a “buy” rating on the stock.
4/17/2024 – Thermo Fisher Scientific had its price target raised by analysts at HSBC Holdings plc from $630.00 to $660.00. They now have a “buy” rating on the stock.
4/10/2024 – Thermo Fisher Scientific had its price target raised by analysts at The Goldman Sachs Group, Inc. from $550.00 to $640.00. They now have a “buy” rating on the stock.
4/4/2024 – Thermo Fisher Scientific had its price target raised by analysts at Evercore ISI from $575.00 to $610.00. They now have an “outperform” rating on the stock.
3/18/2024 – Thermo Fisher Scientific is now covered by analysts at Citigroup Inc.. They set a “neutral” rating and a $620.00 price target on the stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $2.94 during mid-day trading on Thursday, reaching $572.05. The company’s stock had a trading volume of 530,042 shares, compared to its average volume of 1,537,101. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The business has a 50 day moving average price of $575.03 and a 200-day moving average price of $531.97. The firm has a market cap of $218.36 billion, a price-to-earnings ratio of 36.69, a PEG ratio of 2.36 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders sold 62,277 shares of company stock worth $35,373,364 in the last quarter. 0.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 0.6% during the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after buying an additional 50,736 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock valued at $4,240,824,000 after buying an additional 517,137 shares in the last quarter. Norges Bank bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $2,909,524,000. Finally, Northern Trust Corp grew its position in Thermo Fisher Scientific by 2.6% in the third quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock worth $1,988,856,000 after acquiring an additional 99,377 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.